Cue Biopharma, Inc. (CUE)
27.66
+5.33
(+23.87%)
USD |
NASDAQ |
Oct 09, 16:00
27.87
+0.21
(+0.76%)
After-Hours: 20:00
Cue Biopharma Net Income (Quarterly) : -153.07M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -153.07M |
| March 31, 2026 | -5.178M |
| December 31, 2025 | 1.585M |
| September 30, 2025 | -7.448M |
| June 30, 2025 | -8.482M |
| March 31, 2025 | -12.26M |
| December 31, 2024 | -9.496M |
| September 30, 2024 | -8.66M |
| June 30, 2024 | -10.17M |
| March 31, 2024 | -12.35M |
| December 31, 2023 | -13.43M |
| September 30, 2023 | -11.00M |
| June 30, 2023 | -13.18M |
| March 31, 2023 | -13.11M |
| December 31, 2022 | -14.59M |
| September 30, 2022 | -10.96M |
| June 30, 2022 | -13.21M |
| March 31, 2022 | -14.26M |
| December 31, 2021 | -8.384M |
| Date | Value |
|---|---|
| September 30, 2021 | -12.99M |
| June 30, 2021 | -10.28M |
| March 31, 2021 | -12.50M |
| December 31, 2020 | -11.10M |
| September 30, 2020 | -10.03M |
| June 30, 2020 | -10.83M |
| March 31, 2020 | -12.82M |
| December 31, 2019 | -8.917M |
| September 30, 2019 | -6.99M |
| June 30, 2019 | -9.522M |
| March 31, 2019 | -11.27M |
| December 31, 2018 | -11.62M |
| September 30, 2018 | -12.56M |
| June 30, 2018 | -7.30M |
| March 31, 2018 | -7.523M |
| December 31, 2017 | -10.44M |
| September 30, 2017 | -5.032M |
| September 30, 2016 | -2.024M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Xilio Therapeutics, Inc. | -6.373M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 7.877M |
| Total Expenses (Quarterly) | 160.94M |
| EPS Diluted (Quarterly) | -24.14 |
| Enterprise Value | 136.06M |
| Gross Profit Margin (Quarterly) | 99.54% |
| Profit Margin (Quarterly) | -1.94K% |
| Earnings Yield | -97.62% |
| Normalized Earnings Yield | -107.40 |